TICKERNERD
Menu
ARVNARVNHealthcare · Biotechnology

ARVN Stock Forecast: Arvinas, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$7.51
+0.81% on the day

The 16 Wall Street analysts covering Arvinas, Inc. hold a median 12-month price target of $13 — +73.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$478.0M
Ticker Nerd rank
69 / 100
Median analyst target
$13
Analysts covering
16
Revenue$249.7M+1014.7% y/y
Operating income$164.1M
Net income$169.4M
Free cash flow−$48.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.1%
1M
−17.3%
YTD
−36.7%
1Y
−23.0%
From 52W high
−45.7%
From 52W low
+7.6%
$7
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arvinas, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
69 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
93
Issuance
79
Revisions
75
Volatility
62
Size
53
Growth
48
Momentum
42
Value
40
Accruals
32

Quality (93): The business earns solid, repeatable profits on what it owns.

Accruals (32): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26ARVNHigh $21Median $13Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
7 Buy8 Hold1 Sell
Low $6Median $13High $21

The green dot is the last close — the median target sits +73.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
10 Aug 2026CitigroupMaintainsBuy$24 → $21
10 Aug 2026Evercore ISI GroupMaintainsOutperform$19 → $14
5 Aug 2026WedbushMaintainsNeutral$11 → $12
5 Aug 2026Wells FargoDowngradeEqual-Weight$15 → $11
4 Aug 2026BTIGReiteratesBuy$18
3 June 2026Stephens & Co.ReiteratesOverweight$18
3 June 2026Stephens & Co.ReiteratesOverweight—
13 May 2026BarclaysMaintainsOverweight—
13 May 2026BTIGMaintainsBuy—
4 May 2026CitigroupMaintainsBuy—
19 Mar 2026BTIGMaintainsBuy—
19 Mar 2026CitigroupMaintainsBuy—
5 Mar 2026CitigroupMaintainsBuy—
25 Feb 2026Evercore ISI GroupMaintainsOutperform—
25 Feb 2026Piper SandlerReiteratesOverweight—
25 Feb 2026WedbushMaintainsNeutral—
6 Jan 2026CitigroupUpgradeBuy—
17 Dec 2025BarclaysMaintainsOverweight—
10 Nov 2025Stephens & Co.MaintainsOverweight—
6 Nov 2025BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARVN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ARVN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Arvinas, Inc. returned −23.0% against +16.2% for the S&P 500, dividends included.

ARVN vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140Jan 26Apr 26Jul 26Oct 26ARVNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
10
Analysts cutting
0
Fundamentals

Arvinas, Inc. (ARVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
28.1×

Cheaper than 27% of US stocks

Price / sales
1.5×

Cheaper than 59% of US stocks

Price / book
0.8×

Cheaper than 76% of US stocks

EV / EBITDA
8.3×

Cheaper than 44% of US stocks

Growth & margins
Revenue growth (YoY)
1014.7%

Higher than 99% of US stocks

Earnings growth (YoY)
1014.7%

Higher than 97% of US stocks

Gross margin
—
Operating margin
66.4%

Higher than 99% of US stocks

Net margin
2.9%

Higher than 55% of US stocks

Returns & dividend
Return on equity
1.6%

Higher than 47% of US stocks

Return on assets
−1.0%

Higher than 40% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Arvinas, Inc. (ARVN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arvinas, Inc. has a market value of $478.0M and an enterprise value of −$81.9M.

  • Revenue in the twelve months to 30 June 2026: $316.7M. The latest quarter grew 1014.7% year on year.

  • Net income over the same four quarters: $9.3M, a 2.9% net margin.

  • Diluted earnings per share, trailing twelve months: $0.10.

  • Free cash flow in the twelve months to 30 June 2026: −$208.8M.

  • Shares outstanding: 65.3M.

  • Trailing P/E: 28.1×; forward P/E: −2.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Arvinas, Inc. employs 246 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

ARVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARVNArvinas, Inc.$478.0M
69
PROKProKidney Corp.$501.0M
32
ALLOAllogene Therapeutics, Inc.$463.8M
80
PRTAProthena Corp. Plc$463.5M
98
CAPRCapricor Therapeutics, Inc.$460.7M
16
ALTAltimmune, Inc.$505.3M
30
DRUGBright Minds Biosciences, Inc.$506.1M
44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arvinas, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARVN news & analysis

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease

GlobeNewsWire · 7 Oct 2026positive

Arvinas shared Phase 1 data for ARV-102 in patients with Parkinson’s disease, reporting improvements in an objective measure of impaired eye movement. The company also reported a correlation between reductions in LRRK2 cerebrospinal fluid biomarkers, oculomotor changes, and changes in synaptic biomarkers.

Why it matters — The findings provide early clinical and biomarker data on ARV-102 in Parkinson’s disease for investors following Arvinas’s pipeline.

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders®

GlobeNewsWire · 1 Oct 2026neutral

Arvinas announced that novel biomarker data from its Phase 1 clinical trial of ARV-102, a PROTAC LRRK2 degrader, in participants with Parkinson's disease will be presented as late-breaking oral and poster presentations at the 2026 International Congress of Parkinson's Disease and Movement Disorders, held October 4-8, 2026, in Seoul, Korea.

Why it matters — The presentation of biomarker data at a major scientific congress highlights the progress and visibility of Arvinas' ARV-102 program, which is central to its pipeline in Parkinson's disease.

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 29 Sept 2026neutral

Arvinas granted an inducement award to a newly hired employee, consisting of an option to purchase 64,766 shares of common stock and 42,388 restricted stock units, effective September 28, 2026. The grant was made under Nasdaq Listing Rule 5635(c)(4) rather than through the company's stock incentive plan.

Why it matters — This is a routine equity inducement grant tied to a new hire, offering insight into Arvinas' compensation practices but carrying no direct operational or financial signal for shareholders.

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate

GlobeNewsWire · 28 Sept 2026positive

Arvinas announced that the first patient has been dosed in a Phase 1/2 clinical trial of ARV-6723, the company's first immuno-oncology candidate. ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors.

Why it matters — This marks Arvinas's entry into immuno-oncology with the initiation of its first clinical trial for ARV-6723, expanding the company's pipeline beyond its existing programs.

FAQ

Frequently asked questions about ARVN stock

What is the ARVN stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Arvinas, Inc. have a median 12-month price target of $13, with estimates ranging from $6 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARVN stock a buy right now?

Of the 16 analysts covering Arvinas, Inc., 7 rate it a Buy, 8 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Arvinas, Inc. 69 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARVN?

As at 8 Oct 2026, Arvinas, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).

Will ARVN stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +73.1% from the last close, and Ticker Nerd's factor model ranks Arvinas, Inc. 69 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARVN stock forecast for 2030?

No analyst covering Arvinas, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $21 over the next 12 months.

How has ARVN stock performed over the past year?

Arvinas, Inc. returned -23.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arvinas, Inc. do?

Arvinas, Inc. is a clinical-stage biotechnology company focused on targeted protein degradation.

What is the latest news on ARVN?

The most recent item we track (GlobeNewsWire, 7 Oct 2026): "Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease". Arvinas shared Phase 1 data for ARV-102 in patients with Parkinson’s disease, reporting improvements in an objective measure of impaired eye movement. The company also reported a correlation between reductions in LRRK2 cerebrospinal fluid biomarkers, oculomotor changes, and changes in synaptic biomarkers.

Company

About Arvinas, Inc.

Arvinas, Inc. is a clinical-stage biotechnology company focused on targeted protein degradation. The company develops therapies designed to harness the body’s natural protein disposal system to selectively degrade disease-causing proteins, using its proprietary PROTAC platform. Its current pipeline includes investigational programs in oncology and neuroscience, with candidates aimed at hormone-driven cancers, mutated cancers, lymphoma, and neurodegenerative disorders. Arvinas also advances collaboration-based programs alongside wholly owned assets, reflecting a business model centered on drug discovery, clinical development, and strategic partnerships. Headquartered in New Haven, Connecticut, Arvinas plays a notable role in the biopharmaceutical market as a developer of next-generation medicines intended to address difficult-to-treat diseases through a differentiated protein-degradation approach.

CEO Dr. Randy Teel Ph.D. · 246 employees · United States · https://www.arvinas.com